Abstract

This study characterizes the expression and the biological effects of the nicotinic acetylcholine receptor (nAChR) on human airway epithelial cells. Cultured HBE16 airway epithelial cells were incubated with either nicotine or cigarette smoke extract (CSE). The nAChR gene and protein expression in cells were detected by reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR, and western blot. The protein expression of the nAChR subunits, α1, α5, and α7, were evaluated by immunohistochemistry. Cells were subsequently transfected with α1-, α5-, and α7-specific siRNAs, and the effects of nicotine on the production of the pro-inflammatory factors, TNF-α, IL-8, and IL-6 in transfected cells were analyzed using an enzyme-linked immunosorbent assay and real-time PCR. We detected α1, α5, α7, and β2 subunits in untreated HBE16 cells, and their expression was elevated after nicotinic incubation. Importantly, the most significant increase in expression was observed in the α5 and α7 subunits. However, CSE did not cause a significant enhancement in the expression of these genes and proteins. Cells pretreated with nicotine prior to lipopolysaccharide (LPS) stimulation exhibited a lower production of TNF-α, IL-8, and IL-6 compared to LPS-treated (only) cells. Cells that were transfected with α7 siRNA and subsequently incubated with nicotine and LPS, exhibited a higher expression of TNF-α, IL-8, and IL-6 compared with non-transfected cells or α1 and α5 siRNA-transfected cells. In α1- and α5-siRNA-transfected cells, the expression of TNF-α, IL-8, and IL-6 showed no significant difference compared with non-transfected cells. Therefore, we concluded that α1, α5, α7, and β2 nAChR subunits are highly expressed in human bronchial epithelial cells (HBE16) after nicotinic incubation and that the α7 subunit is involved in the nicotine-induced inhibitory effect on the production of inflammatory factors. Moreover, α1, α5, and β2 subunits did not play an important role in this process.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.